Kurzfassung

A phase III, randomized, open-label, multi-center, global study of MEDI4736 in combination with Tremelimumab therapy or MEDI4736 monotherapy versus standard of care platinum-based chemotherapy in first-line treatment of patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC)